Subscribe to RSS
DOI: 10.4103/1947-489X.210963
A new perspective on HIV vaccine design: A viewpoint
The unsuccessful outcome of a number of vaccine trials in the quest to conquer HIV-1 demonstrates the difficulties inherent in fighting diseases that afflict our world, and the poor disproportionately, especially the developing nations. A quarter century has elapsed since AIDS became a recognized major threat to human health, yet the evergrowing volume of scientific data has failed to meet its prime objective, a cure for AIDS or an HIV prevention vaccine. This brief article suggests several intriguing possibilities for researchers to consider, including small RNA-based immunity, as they seek to find a vaccine for the HIV-1 infection that threatens not only individuals and families, but in some cases entire nations.
Key-words:
African non-human primates (ANHPs) - Classical immunity (CI) - Cell-mediated immunity (CMI) - elite suppressor (ES) - Humoral immunity (HI) - innate immunity - long-term nonprogressor (LTNP) - microRNAs (miRNAs) - molecular immunity (MI) - VaccinePublication History
Received: 11 September 2009
Accepted: 26 October 2009
Article published online:
23 May 2022
© 2010. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India